title: Persistence of molecular remission throughout pregnancy in CML after imatinib.
authors.forename: Federica
authors.initials: F
authors.lastname: Sorà
authors.forename: Silvia
authors.initials: S
authors.lastname: De Matteis
authors.forename: Jolanta
authors.initials: J
authors.lastname: Bajer
authors.forename: Francesco
authors.initials: F
authors.lastname: D'alò
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Leone
authors.forename: Simona
authors.initials: S
authors.lastname: Sica
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate